Contineum (CTNM) news
Recent news
Stifel raises target price to $29 from $28
Stifel has raised its price target for Contineum stock to $29 from $28, reiterating its Buy rating on the company. The adjustment reflects the firm’s continued confidence in Contineum’s strategic direction and operational performance. The stock currently trades near this updated price target,…
AInvest Wire · Aug 20, 2026Contineum Therapeutics Inc Q2 net loss per share $0.40
Contineum Therapeutics Inc. (NASDAQ: CTNM) reported a net loss per share of $0.40 for the second quarter of 2026, according to its most recent financial results. This figure reflects the company’s ongoing investment in clinical development and operational expansion as it advances its pipeline of…
AInvest Wire · Jul 30, 2026Contineum Therapeutics - implements workforce reduction including chief scientific officer Daniel Lorrain
Contineum Therapeutics (NASDAQ: CTNM) has announced a workforce reduction as part of a strategic restructuring initiative, which includes the departure of Daniel S. Lorrain , the company’s Chief Scientific Officer. The move is intended to streamline operations and align resources with the company’s…
AInvest Wire · Jul 30, 2026Contineum raises US$110m in downsized IPO
AInvest Wire · Apr 5, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.